Innovative Molecules GmbH
🇩🇪Germany
Clinical Trials
2
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)phase_1_2
1 (50.0%)Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Doses of IM-250 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Herpes Simplex Virus
- Interventions
- Drug: IM-250 (50 mg)Drug: IM-250 (200 mg)Drug: IM-250 (400 mg)Drug: IM-250 (100 mg)
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Innovative Molecules GmbH
- Target Recruit Count
- 18
- Registration Number
- NCT06435507
- Locations
- 🇩🇪
University Hospital Heidelberg, Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg, Germany
News
Innovative Molecules Completes Phase 1b Enrollment for Novel HSV Inhibitor IM-250
Innovative Molecules GmbH has completed enrollment in the Phase 1b portion of its clinical trial evaluating IM-250, a next-generation helicase-primase inhibitor for recurrent genital herpes.